Twist Bioscience Corporation $TWST Stock Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al decreased its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 54.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,238 shares of the company’s stock after selling 8,700 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Twist Bioscience were worth $1,399,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Twist Bioscience during the second quarter worth approximately $600,191,000. William Blair Investment Management LLC acquired a new stake in Twist Bioscience in the 2nd quarter valued at $223,722,000. Bank of America Corp DE acquired a new stake in Twist Bioscience in the 2nd quarter valued at $94,922,000. Allspring Global Investments Holdings LLC acquired a new stake in Twist Bioscience in the 1st quarter valued at $22,563,000. Finally, Bank of New York Mellon Corp acquired a new stake in Twist Bioscience in the 2nd quarter valued at $19,722,000.

Wall Street Analyst Weigh In

A number of analysts have commented on TWST shares. Guggenheim boosted their price target on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Leerink Partners raised their price objective on shares of Twist Bioscience from $160.00 to $190.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. TD Cowen boosted their target price on shares of Twist Bioscience from $115.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Finally, UBS Group started coverage on shares of Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $153.00.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $142.58 on Thursday. The company has a market cap of $8.94 billion, a PE ratio of -64.22 and a beta of 2.25. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $219.71. The business has a 50 day moving average price of $152.59 and a 200-day moving average price of $90.28. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.33 EPS. Equities analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 2,462 shares of the firm’s stock in a transaction on Friday, October 9th. The stock was sold at an average price of $156.30, for a total transaction of $384,810.60. Following the transaction, the chief financial officer directly owned 98,114 shares in the company, valued at approximately $15,335,218.20. This trade represents a 2.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of Twist Bioscience stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the transaction, the senior vice president directly owned 106,632 shares in the company, valued at $20,140,652.16. This represents a 8.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 601,920 shares of company stock valued at $93,768,202 in the last three months. Insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.